Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Comment Review Concerns Prompt Request For Second GAO Report

This article was originally published in The Tan Sheet

Executive Summary

A request by Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) for a GAO investigation into FDA's outsourcing of public comment review for Plan B is the latest effort by the lawmakers to encourage a decision on the Rx-to-OTC switch application

You may also be interested in...



Plan B ANPR Comments Undergoing Independent Contractor Review

Plan B comment analysis is being handled by an outside contractor with oversight by FDA's Office of Policy, according to Acting Commissioner Andrew von Eschenbach, MD

GAO Draft Report Finds Plan B Rejection “Unusual”; Lawmakers Urge Decision

The Government Accountability Office's investigation into FDA's initial denial of Plan B discovered that the agency's decision to issue a "not approvable" letter did not reflect the opinions of scientific review staff.

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel